Navigation Links
Perrigo Acquires Rights to Generic Version of HalfLytely® from Novel Laboratories
Date:5/26/2010

ALLEGAN, Mich., May 26 /PRNewswire-FirstCall/ -- Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has acquired rights to Novel Laboratories' pending ANDA for HalfLytely® and Bisacodyl Tablets Bowel Prep Kit (PEG-3350, sodium chloride, sodium bicarbonate and potassium chloride for oral solution and bisacodyl delayed-release tablets), indicated for the cleansing of the colon as a preparation for colonoscopy in adults. Annual sales for the Braintree Laboratories brand were approximately $80 million according to Wolters Kluwer.

Novel Laboratories believes it was first to file an ANDA containing a Paragraph IV Certification with the U.S. Food & Drug Administration, and therefore the product is expected to be approved with 180 days of generic exclusivity. The brand marketing exclusivity ends on September, 24, 2010. The company has not been sued. Under terms of the Perrigo/Novel agreement, Novel will manufacture the product exclusively for Perrigo.

Perrigo's Chairman and CEO Joseph C. Papa concluded, "This acquisition is another example of Perrigo's ongoing commitment to solidify our leadership position in the generic extended topical space, and to deliver quality, affordable healthcare products to retailers and consumers.  Novel has a strong track record of bringing high-value first generic products into the market, and we look forward to our collaboration."        

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and generic prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products. The Company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. The Company's primary markets and locations of manufacturing and logistics operations are the United States, Australia, Israel, Mexico and the United Kingdom. Visit Perrigo on the Internet (http://www.perrigo.com).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections.  While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 27, 2009, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Perrigo Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Perrigo Company to Present at the Citi Investment Research Global Health Care Conference
2. Perrigo Company Announces Quarterly Dividend
3. Perrigo Acquires Infant Formula Manufacturer PBM Holdings for $808 Million
4. Perrigo Company Announces Quarterly Dividend
5. Perrigo Company Will Release Second Quarter Fiscal 2010 Results on February 2, 2010
6. Perrigo Company to Present at the 28th Annual J.P. Morgan Healthcare Conference
7. Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix
8. Perrigo Company To Present at the Sidoti Emerging Growth Conference
9. Perrigo Company Announces Dividend Increase
10. Perrigo Company Will Release First Quarter Fiscal 2010 Results on November 2, 2009
11. Perrigo Confirms Filing for Generic Version of Mens Rogaine(R) Foam
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Mar. 24, 2017 Research and Markets has announced ... Growth and Demand Forecast to 2022" report to their offering. ... The global wound care market ... at a CAGR of 6.7% during 2016-2022 Among the various ... largest share in the global market in 2015. Among the various applications, ...
(Date:3/24/2017)... NEW YORK , March 24, 2017 ... ... Research, a leading publisher of cannabis market research, the legal ... 27 percent CAGR through 2021, despite conflicting signals from the ... Analytics, points out that the two biggest drivers of growth ...
(Date:3/24/2017)... Global Ampoules Market report provides ... applications and industry chain structure. The Ampoules market analysis ... competitive landscape analysis, and major regions, development status. ... ... providing 10 company profiles and 183 tables and figures ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... In 2016 the World Health ... there could be four million Zika-related cases in the Americas within the next year. ... US cases reported per year skyrocketing to an estimated 329,000. Yet, Zika, Lyme and ...
(Date:3/23/2017)... ... March 23, 2017 , ... Demonstrating their commitment to ... public health departments have been awarded national accreditation through the Public Health ... the expanding network of communities across the nation whose health departments meet rigorous ...
(Date:3/23/2017)... Minneapolis, MN (PRWEB) , ... March 23, 2017 , ... ... with internet and WiFi connectivity are making a huge impact on businesses and individual ... Global Institute estimates the IoT will have a value anywhere from $4 trillion to ...
(Date:3/23/2017)... ... March 23, 2017 , ... Dilger-Maxwell ... of the Norwalk and Vermillion areas, celebrates the newest charity campaign in ... nonprofit, community-based substance abuse prevention and peer recovery support organization providing vital ...
(Date:3/23/2017)... ... March 23, 2017 , ... The StayWell Company announced today ... accreditation covers StayWell’s asthma, coronary artery disease, congestive heart failure, chronic obstructive pulmonary ... have excellent programs for the delivery and improvement of disease management and that ...
Breaking Medicine News(10 mins):